Moderna explores development of combo vaccine

Jan. 18, 2022

A potential combination vaccine that offers protection against COVID-19, influenza and RSV could be on the market by fall of 2023, announced Stéphane Bancel, CEO of Moderna Therapeutics.

During a panel at the World Economic Forum, Bancel shared his hopes that the combo vaccine would reduce the amount of shots people need to get each winter, making getting vaccinated easier and hopefully increasing compliance.

"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter," said Bancel.

The best-case scenario would have the vaccine on the market by fall of 2023 in some countries.

In September, the company announced it was working on a single shot to combine a COVID-19 booster with its experimental flu shot. At the time, Moderna mentioned the possibility of also adding a potential RSV vaccine to the combo.

During the Davos panel, Bancel also shared that the omicron-specific vaccine Moderna has been developing since the initial surge of the variant in Nov. is now just weeks away from the clinic. The company expects data to be shared with regulators around March.